Therapy of diabetes and dyslipidemia in acromegaly

Pituitary

Volumn 5, Issue 1, 2002, Pages 27-31

  Tamburrano, G ^a   Durante, C ^a   Baldelli, R ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; C PEPTIDE; CHOLESTEROL; CIGLITAZONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENGLITAZONE; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; ISOXAZOLIDINE DERIVATIVE; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PROTEIN KINASE C INHIBITOR; RETINOID X RECEPTOR; ROSIGLITAZONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VANADIC ACID;

ACROMEGALY; ARTICLE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GROWTH HORMONE RELEASE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; MORBIDITY; MORTALITY; NEUROSURGERY; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ACROMEGALY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS;

EID: 0036462235     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022101417810     Document Type: Article

References (46)

1. Bates AS, vant'Hoff W, Jones JM, Clayton R. An audit of outcome of treatment in acromegaly. Quarter J Med 1993;86:293-299.
2. Foss MC, Saad JA, Paccola GM, Paula JA, Piccinato CE, Moreira AC. Peripheal glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991;72(5):1048.
3. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: Defects in both hepatic and extrahepatic insulin action. Am I Physiol 1986;250:269.
4. Jap TS, Ho LT. Insulin secretion and sensitivity in acromegaly. Clin Physiol Biochem, 1990;8:64-69.
5. Reaven GM. Role of insulin resistance in human disease. Banting lecture. Diabetes 1988;37:1595-1607.
6. De Fronzo RA, Ferranini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, amd atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
7. Reaven GM. A syndrome of resistance to insulin-stimulated glucose uptake (Syndrome X): Definition and implication. Cardiovasc Risk Fact 1993;3:2-11.
8. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;82:2777-2781.
9. Lawrence JH, Tobias CA, Linfodt JA, Barnn J, Lyman T, Chang CY, Manaugian E, Wei WC. Successfull treatment of acromegaly: Metabolic and clinical studies in 145 patients. J Clin Endocrinol Metab 1970;31:180-188.
10. Beck P, Schalch D, Parker M, Kipnis D, Daughaday W. Correlation studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly. J Lab Clin Med 1965;66:366-379.
11. Campbell J, Rastogi K. Growth hormone-induced diabetes and high levels of serum insulin in dogs. Diabetes 1966;15:30-43.
12. Clayton R, Vrionides Y, Lynch S, Butt W, London D. Responses of acromegaly to long-term bromocriptine therapy: A biochemical and clinical assessment. Acta Endocrinol 1978;89:469-482.
13. Fineberg S, Merimee T. Acute metabolic effects of human growth hormone. Diabetes 1974;23:499-504.
14. Roelfsema F, Goslings B, Frolich M, Moolenaar A, VanSeters A, VanSlooten H. The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly. Clin Endocrinol 1979;11:235-244.
15. Gama R, Teale JD, Wright J, Ferns G, Marks V. Hyperproinsulinaemia in acromegaly: Evidence for abnormal pancreatic beta-cell function. Ann Clin Biochem, 1997;34:627-631.
16. Muggeo M, Robert S Bar, Roth J, Kahn R. The insulin resistance of acromegaly: Evidence for two alterations in the insulin receptor on circulating monocytes. J Clin Endocrinol Metab 1979;48:17.
17. Takeda R, Tatami R, Ueda K, Sagra H, Nakabayashi H, Mabuchi H. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinologica 1982;100:358-362.
18. Tan KCB, Shiu SWM, Janus ED, Lam KS. LDL subfractions in acromegaly: Relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 1997;129:59-65.
19. Nikkila EA, Pelkonen R. Serum lipid in acromegaly. Metabolism 1975;24:829-838.
20. Maffei P, Sicolo N, Plebani M. Lipoprotein(a) in acromegaly. Annals of Internal Medicine 1999;130(6):537-538.
21. Damjanovic SS, Petakov MS, Raicevic S, Micic D, Marinkovic J, Dieguez C, Casanueva FF, Popovic V. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by transsphenoidal surgery. J Clin Endocrinol Metab 2000;85:147-154.
22. Baldelli R, Dieguez C, Casanueva FF. The role of leptin in reproduction: Experimental and clinical aspects. Ann Med 2002;34(1):5-18.
23. Janssen YJH, Frölich M, Deurenberg P, Roelfsema F. Serum leptin levels during recombinant human GH therapy in adults with GH deficiency. Eur J Endocrinol 1997;137:650-654.
24. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J, Caro JF. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996;45:699-701.
25. Malmstrom R, Taskinen M-R, Karonen S-L, Yki-Jarvinen H. Insulin increases plasma leptin in normal subjects and patients with NIDDM. Diabetologia 1996;39:993-996.
26. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987;26(4): 481-512.
27. Roelfsema F, Frolich M. Glucose tolerance and plasma immunoreactive insulin levels in acromegalics before and after selective transsphenoidal surgery. Clin Endocrinol (Oxf) 1985;22(4):531-537.
28. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J. Hormonal and metabolic effects of radiotherapy in acromegaly: Long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000;85(10):3779-3785.
29. Ho KK, Jenkins AB, Furler SM, Borkman M, Chisholm DJ. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992;36(3):271-279.
30. Vance ML, Harris AG. Long term treatment of 189 acromegalic patients with soamtostatin analog octreotide. Arch Intern Med 1991;151:1573-1578.
31. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 1994;130(6):581-586.
32. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study, Italian Multicenter Octreotide Study Group. Eur J Endocrinol 1995;133:430-439.
33. Hirose T, Kuroda T, Otsuki M, Takagi M, Yamamoto H, Motomura T, Kurebayashi S, Miyashita Y, Koga M, Arita N, Hayakawa T, Kishimoto T, Kasayama S. A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide. Intern Med 1997;36(5):345-350.
34. Hizuka N. Divergent effects of octreotide on glucose tolerance in patients with acromegaly. Intern Med 1997;36(5):319-320.
35. Lewitt MS, Baxter RC. Insulin-like growth factor-binding protein-1: A role in glucose counterregulation? Mol Cell Endocrinol 1991;79(1-3):C147-C152.
36. Ezzat S, Ren SG, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: A potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992;75(6):1459-1463.
37. Caron O, Morange-Ramos I, Cogne M, Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
38. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: Long-term treatment. J Clin Endocrinol Metab 1997;82(1):23-28.
39. Parkinson C, Drake WM, Roberts ME, Meeran K , Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002;87(4):1797-1804.
40. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21(3):713-735.
41. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinal Metab 1990;71(2):391-397.
42. Simsolo RB, Ezzat S, Ong JM, Saghizadeh M, Kern PA. Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase. J Clin Endocrinol Metab 1995;80(11):3233-3238.
43. Lam KS, Pang RW, Janus ED, Kung AW, Wang CC. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 1993;104(1/2):183-188.
44. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000;151:551-557.
45. Wildbrett J, Hanefeld M, Fucker K, Pinzer T, Bergmann S, Siegert G, Breidert M. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 1997;105(6):331-335.
46. Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE. Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome. Metabolism 1996;45(10):1263-1266.